Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study

Table 9 Association of the ADRs costs with study groups and study participants’ characteristics

Parameter	B	95% LCI	95%UCI	Exp(B)	95% LCI	95% UCI	p value
(Intercept)	3.689	1.324	6.054	39.99	3.757	425.62	0.002
Study arm	0.908	0.348	1.469	2.48	1.416	4.344	0.001
Gender	0353	− 0.193	0.9	1.424	0.824	2.459	0.205
Smoking	0.282	− 0.187	0.751	1.326	0.83	2.119	0.238
Hypertension	0.662	0.12	1.203	1.939	1.128	3.332	0.017
Diabetes	1.593	1.152	2.034	4.917	3.163	7.644	0.000
Age	0.001	− 0.023	0.023	1	0.977	1.023	0.992
BMI	− 0.015	− 0.064	0.033	0.985	0.938	1.034	0.536
(Scale)	87.652^a	77.35	99.32

Dependent Variable: Total Cost; Generalized Linear Model; Tweedie distribution with log-link function; Model: (Intercept), Study arm, Gender, Smoking, Hypertension, Diabetes, Age, BMI
^aMaximum likelihood estimate
LCI Lower Confidence Interval, UCI Upper Confidence Interval

ISSN: 1479-7364